Standard- vs high-dose clopidogrel after percutaneous coronary intervention.

摘要

To the Editor: The results of the Gauging Responsiveness with a VerifyNow assay-Impact on Thrombosis and Safety (GRAVITAS) and Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7) trials suggested that high-dose clopidogrel after percutaneous coronary intervention (PCI) can exhibit different clinical efficacy according to the study design. CURRENT-OASIS 7 found a reduction in cardiovascular death, myocardial infarction (MI), or stroke at 1 month with double-dose clopidogrel (adjusted hazard ratio [HR], 0.86) while GRAVITAS, after 6 months, did not (HR, 1.01).